Biocept announces a delay in the filing of its quarterly report on form 10-q

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products, and services, announces a delay in the filing of its quarterly report on form 10-q for the quarter ended june 30, 2022. the delay is related to the ongoing accounting review of biocept's financial statements as of and for the three months ended june 30, 2022, which ongoing review includes the analysis of previously reported material weaknesses and matters related to the u.s. he
BIOC Ratings Summary
BIOC Quant Ranking